Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid

1995 ◽  
Vol 191 (1-2) ◽  
pp. 79-82 ◽  
Author(s):  
Adam Golabek ◽  
Marcos A. Marques ◽  
Maciej Lalowski ◽  
Thomas Wisniewski
2002 ◽  
Vol 8 (7) ◽  
pp. 376-381 ◽  
Author(s):  
Zhongmin Zhou ◽  
Norman Relkin ◽  
Jorge Ghiso ◽  
Jonathan D. Smith ◽  
Sam Gandy

2009 ◽  
Vol 34 (3) ◽  
pp. 209-212 ◽  
Author(s):  
Mads Hansen ◽  
JøSrn Brynskov ◽  
Peter Anders Christensen ◽  
Jens Jakob Krintel ◽  
Peter Gimsing

2010 ◽  
Vol 9 (9) ◽  
pp. 2063-2075 ◽  
Author(s):  
Marcel P. Stoop ◽  
Leon Coulier ◽  
Therese Rosenling ◽  
Shanna Shi ◽  
Agnieszka M. Smolinska ◽  
...  

PLoS ONE ◽  
2010 ◽  
Vol 5 (6) ◽  
pp. e10980 ◽  
Author(s):  
Steven E. Schutzer ◽  
Tao Liu ◽  
Benjamin H. Natelson ◽  
Thomas E. Angel ◽  
Athena A. Schepmoes ◽  
...  

1959 ◽  
Vol 100 (3) ◽  
pp. 607-608 ◽  
Author(s):  
L. M. Meyer ◽  
R. W. Bertcher ◽  
C. Mulzac

1999 ◽  
Vol 43 (8) ◽  
pp. 1932-1934 ◽  
Author(s):  
Markus Nagl ◽  
Claudia Neher ◽  
Josef Hager ◽  
Bettina Pfausler ◽  
Erich Schmutzhard ◽  
...  

ABSTRACT Intraventricular application of vancomycin is an effective therapeutic regimen for the treatment of shunt-associated staphylococcal ventriculitis. We examined the in vitro activity of vancomycin at high concentrations against Staphylococcus aureus ATCC 25923 and Staphylococcus epidermidis ATCC 12228 in human cerebrospinal fluid samples. Time-kill curves revealed equal efficacies for concentrations of 10, 100, and 300 μg/ml, and incubation times of 24 to 48 h were needed to achieve a 3 log10 reduction of viable bacteria. A concentration of 5 μg/ml showed a slightly lower activity, but this difference was not significant. In an infant who was successfully treated for shunt-associated ventriculitis due to S. epidermidis by once-daily local administration of vancomycin (3 mg for 2 days and 5 mg for 4 days [0.5 to 0.8 mg/kg of body weight]) the in vivo kill kinetics were similar to those for the in vitro results. These results support time-dose regimens that provide trough vancomycin levels of 5 to 10 μg/ml.


2018 ◽  
Vol 66 (3) ◽  
pp. 1053-1064 ◽  
Author(s):  
M. Mahafuzur Rahman ◽  
Gunilla T. Westermark ◽  
Henrik Zetterberg ◽  
Torleif Härd ◽  
Mats Sandgren

1991 ◽  
Vol 4 (4) ◽  
pp. 192-200 ◽  
Author(s):  
Fernando Commodari ◽  
Douglas L. Arnold ◽  
Bryan C. Sanctuary ◽  
Eric A. Shoubridge

Sign in / Sign up

Export Citation Format

Share Document